Juncture Wealth Strategies LLC Increases Stake in Cellebrite DI Ltd. (NASDAQ:CLBT)

Juncture Wealth Strategies LLC boosted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 60,003 shares of the company’s stock after purchasing an additional 505 shares during the quarter. Juncture Wealth Strategies LLC’s holdings in Cellebrite DI were worth $1,322,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Quarry LP acquired a new position in Cellebrite DI in the 3rd quarter worth $27,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in Cellebrite DI by 59.6% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after purchasing an additional 1,017 shares during the last quarter. Advisors Asset Management Inc. grew its stake in Cellebrite DI by 130.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new position in shares of Cellebrite DI in the 2nd quarter valued at approximately $71,000. Finally, Pathway Financial Advisers LLC raised its holdings in Cellebrite DI by 1,583.8% in the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after acquiring an additional 4,118 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analysts Set New Price Targets

CLBT has been the subject of several research analyst reports. Craig Hallum boosted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Finally, Needham & Company LLC lifted their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI has a consensus rating of “Buy” and a consensus price target of $21.57.

Cellebrite DI Price Performance

NASDAQ:CLBT opened at $23.70 on Friday. Cellebrite DI Ltd. has a 1 year low of $8.73 and a 1 year high of $24.18. The business has a fifty day moving average of $21.29 and a 200-day moving average of $18.00.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $106.90 million during the quarter, compared to analysts’ expectations of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business’s revenue was up 27.0% on a year-over-year basis. During the same period last year, the firm posted $0.09 earnings per share. Analysts forecast that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.